During IPWatchdog’s Life Sciences Masters program, which is taking place this week from Monday to Wednesday, panelists on the one hand breathed a sigh of relief that certain rule proposals considered most destructive to the industry seem unlikely to move forward, but on the other, lamented the overall negative tenor of the public debate around pharmaceutical patents today.
Recent Posts
- Other Barks & Bites for Friday, February 14: EU Commission Scraps SEP Draft Regulations; Senate Commerce to Explore Spectrum Auction Delays; House Science Seeks Review of Commercial Space Licensing
- Vidal Amicus Asks CAFC to Correct ED of TX Jury Instructions on Eligibility
- Revised Fair Use Ruling Finds No Transformative Use in Developing AI Search Tool
- Patently Strategic Podcast: Dealing with Rejection
- IPWatchdog Unleashed: Patents and the Future of the USPTO in Trump’s Second Term